新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2025-059 新里程健康科技集团股份有限公司 第六届董事会第三十八次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）第六 届董事会第三十八次会议于 2025 年 12 月 10 日以书面、电话、电子邮件等形式 发出，会议于 2025 年 12 月 15 日在公司会议室以现场表决结合通讯表决的方式 召开，本次会议由公司董事长林杨林先生主持，公司现任董事 11 名，实际表决 董事 11 名，公司高级管理人员列席本次会议，会议的召开与表决程序符合《公 司法》和《公司章程》的有关规定，所做决议合法有效。 二、董事会会议审议情况 经与会董事充分讨论，审议通过了以下议案并形成决议。 （一）逐项审议通过《关于公司董事会换届选举非独立董事候选人的议案》 鉴于公司第六届董事会任期已届满，根据《公司法》、《深圳证券交易所股票 上市规则》、《公司章程》等有关规定，公司董事会决定进行换届选举，并组建第 ...

每经AI快讯，新里程（SZ 002219，收盘价：2.23元）12月15日晚间发布公告称，公司第六届第三十八 次董事会会议于2025年12月15日在公司会议室以现场表决结合通讯表决的方式召开。会议审议了《关于 公司董事会换届选举非独立董事候选人的议案》等文件。 2025年1至6月份，新里程的营业收入构成为：医疗行业占比86.85%，医药行业占比13.15%。 截至发稿，新里程市值为76亿元。 （记者 王晓波） 每经头条（nbdtoutiao）——中标企业频频弃标 大型医疗设备采购有何难言之隐？ ...

Core Insights - The "2025 Fifth China Health Industry Development and Rehabilitation Service Conference" was successfully held in Beijing, focusing on integrating resources across the health industry and exploring development paths under the theme "Intelligent Leadership for a Healthy Future" [1] Group 1: Industry Trends and Innovations - The conference featured high-level roundtable discussions on cutting-edge topics such as innovative drugs, brain-machine interfaces, AI in healthcare, and the transformation of traditional Chinese medicine [1] - A series of innovative case studies were released, showcasing advancements in areas like ESG, innovative drugs, biomedicine, AI healthcare, and social psychological services, highlighting the vitality and innovation within the health sector [1] Group 2: Company Highlights - **Jingtai Holdings** utilizes "AI + Robotics + Data" to accelerate drug development, having collaborated with major pharmaceutical companies and significantly expedited the market entry of Pfizer's COVID-19 oral drug Paxlovid by six months [3] - **Meinian Health** leverages AI technology for precise early screening and health management, continuously launching specialized products to meet diverse public health management needs [4] - **Dean Diagnostics** has developed an AI product matrix that enhances medical scene intelligence, achieving comprehensive coverage from hospitals to personal health management [5] - **Yingkang Life** integrates AI deeply into the entire medical service process, significantly improving medical capabilities and operational efficiency through its AI-driven platforms [6][7] - **New Mile Health Technology** is advancing a smart healthcare system that combines online and offline services, enhancing the digital landscape of managed healthcare [8] - **Airdoc** focuses on retinal AI imaging technology for chronic disease early screening and management, having provided diagnostic solutions to over 30 million people [9] - **Aidikang** employs AI-assisted imaging to enhance detection efficiency, achieving a performance rate of 6-7 times that of manual processes in key medical fields [10] - **Yidu Technology** has introduced the "Doctor Copilot" AI platform, which integrates seamlessly into clinical workflows, significantly enhancing the efficiency of healthcare services [11] - **Deepwise Medical** offers multi-modal AI solutions to various healthcare institutions, supporting high-quality development across the medical sector [12] - **Huadensen Bio** focuses on "precision diagnosis" through liquid biopsy technology, utilizing AI to improve the efficiency and accuracy of CTC detection [14]

Core Insights - The rapid development of artificial intelligence (AI) technology is driving unprecedented changes in China, accelerating industry innovation and rapidly restructuring existing industrial value chains [1][2] - The integration of industrial chains, innovation chains, and capital chains is becoming a core path to support industrial upgrades and cultivate new productive forces [1] - The upcoming First Financial Capital Annual Conference on December 18 in Shanghai will focus on "New Momentum, New Milestones," discussing innovation paths and industrial transitions in the context of China's economic development leading up to 2025 [1][2] Event Details - The conference will feature discussions on economic resilience, opportunities and challenges in technological innovation, and the transition of hard technology from "catching up" to "leading" [1][2] - Two specialized roundtable forums will be held, focusing on the valuation logic reshaping in key areas such as chips, new materials, and commercial aerospace, as well as the core competencies that technology companies need to navigate through cycles [2] - An interactive "AI Market" will be set up at the conference to showcase the latest technological achievements and applications, providing attendees with opportunities for close engagement with cutting-edge technologies and company leaders [2] Collaboration and Support - The event is supported by organizations such as Plug and Play China and RobotToday, with participation from various partners to create an efficient and trustworthy industrial service ecosystem [2]

Core Insights - Tesla's Shanghai Gigafactory has achieved a significant milestone by producing its 4 millionth vehicle, contributing nearly half of Tesla's global electric vehicle deliveries [1][3]. Group 1: Production Milestones - The Shanghai Gigafactory began construction in January 2019 and delivered its first Model 3 by December of the same year, showcasing Tesla's rapid production capabilities [3]. - The factory reached the milestone of 1 million vehicles in August 2022 and 3 million vehicles in October 2024, with the latest 1 million vehicles produced in just 14 months [3]. - The factory's production efficiency is highlighted by its ability to produce a vehicle every 30 seconds, making it the highest-capacity vehicle manufacturing facility globally [3]. Group 2: Localization and Supply Chain - The localization rate of the supply chain at the Shanghai Gigafactory has reached 95%, fostering a robust ecosystem for the electric vehicle industry in the Yangtze River Delta region [3]. - The factory collaborates with over 400 Chinese tier-one suppliers, with more than 60 of them integrated into Tesla's global supply chain [3]. Group 3: Export and Expansion - The Shanghai Gigafactory serves as Tesla's global export hub, meeting not only domestic demand but also achieving significant sales in Europe and the Asia-Pacific markets [5]. - In October, the factory recorded its highest monthly export figure in two years, exceeding 35,000 vehicles [5]. - Tesla has expanded its operations in Shanghai beyond vehicle manufacturing, with the establishment of a battery storage factory, marking its first such facility outside the United States [5].

Core Viewpoint - The company is actively developing an "AI + healthcare" strategy, focusing on smart healthcare and elderly care, while integrating online and offline medical services [1] Group 1: Company Strategy - The company is building a comprehensive internet healthcare service system that includes online appointment scheduling, payment, intelligent guidance, report inquiries, online consultations, intelligent companionship, and imaging diagnostics [1] - The company is increasing the promotion of surgical robots to enhance the digital transformation of managed healthcare in China [1] Group 2: Financial Performance - For the period from January to September 2025, the company reported a revenue of 2.256 billion yuan, representing a year-on-year decline of 23.40% (adjusted) [1] - The company experienced a net loss of 38 million yuan, with the loss expanding by 167.83% year-on-year (adjusted) [1]

Core Viewpoint - The successful launch of the Zhuque-3 rocket marks a significant advancement in China's commercial space sector, particularly in the development of large liquid oxygen-methane rockets, despite the failure of the first stage recovery due to abnormal combustion [1][6]. Group 1: Launch and Technical Details - Zhuque-3 rocket was launched on December 3, successfully placing its second stage into the designated orbit, demonstrating important capabilities in large liquid oxygen-methane rocket development [1]. - The rocket has a total length of 66.1 meters, a diameter of 4.5 meters, and a launch mass of approximately 570 tons, with a thrust exceeding 750 tons [2][5]. - The rocket's first stage is designed for vertical return and recovery, equipped with a reaction control system, grid fins, and landing legs [2]. Group 2: Market Reaction and Investment Opportunities - Following the launch, the A-share commercial space sector saw a surge, with stocks like Shanghai Hanxun and Zhaobiao Co. hitting the daily limit, indicating strong market enthusiasm for commercial space ventures [1][2]. - The establishment of the Commercial Space Administration by the National Space Administration and the release of the "Action Plan for Promoting High-Quality and Safe Development of Commercial Space (2025-2027)" are expected to further stimulate the sector [2][8]. Group 3: Future Prospects and Comparisons - The Zhuque-3 rocket is positioned to potentially surpass SpaceX's Falcon 9 within five years, as noted by Elon Musk, highlighting its competitive edge in reusable rocket technology [5][6]. - Other domestic reusable rockets under development include the "Long March 12A" and "Hyperbola 3," indicating a growing competition in the reusable rocket market in China [8].

Core Viewpoint - The successful launch of the Zhuque-3 rocket marks a significant advancement in China's commercial space sector, particularly in the development of large liquid oxygen-methane rockets, despite the failure of the first stage recovery due to abnormal combustion [1][6]. Group 1: Launch and Technical Details - Zhuque-3 rocket was launched on December 3, successfully placing its second stage into the designated orbit, demonstrating important capabilities in large liquid oxygen-methane rocket development [1]. - The rocket has a total length of 66.1 meters, a body diameter of 4.5 meters, and a launch mass of approximately 570 tons, with a thrust exceeding 750 tons [2][5]. - The rocket's first stage is designed for vertical return and reuse, equipped with a reaction control system, grid fins, and landing legs [2][5]. Group 2: Market Reaction and Investment Opportunities - Despite the recovery failure, the capital market remains optimistic about the commercial space sector, with significant stock price increases in related companies such as Shanghai Hanxun and Zhaobiao Co., which hit the daily limit [1][2]. - The establishment of the Commercial Space Administration by the National Space Administration and the release of the "Action Plan for Promoting High-Quality and Safe Development of Commercial Space (2025-2027)" are seen as catalysts for the sector [2][8]. Group 3: Future Prospects and Competitors - Zhuque-3 is positioned as a leading project in China's reusable rocket development, with potential to surpass SpaceX's Falcon 9 within five years, as noted by Elon Musk [5][6]. - Other domestic reusable rockets under development include the "Long March 12A" and "Hyperbola-3," indicating a competitive landscape in China's commercial space industry [8].

Core Viewpoint - The company, Xinli Cheng (002219.SZ), has stated that it is not at risk of being investigated, emphasizing its compliance with legal regulations and commitment to improving corporate governance and fulfilling information disclosure obligations [1]. Group 1 - The company confirmed that there is no risk of being subject to an investigation [1] - The company operates in strict accordance with relevant laws and regulations [1] - The company is focused on continuously enhancing its corporate governance standards [1]

格隆汇12月3日丨新里程(002219.SZ)在互动平台表示，公司暂无发展儿童纸尿裤和成人失禁护理用品的 计划。医疗服务及医药工业是公司目前的核心业务，公司将持续深化"医疗+医药"双轮驱动战略，进一 步完善业务布局，增强健康科技内涵。 ...